This study evaluated the estrogenic and antiestrogenic activities of native and in vitro hepatic metabolized tuberous extracts of wild Butea superba collected from 23 out of the 76 provinces in Thailand by yeast estrogen screening (YES). The YES screen used consisted of the human estrogen receptors hER and hER and the human transcriptional intermediary factor 2 or human steroid receptor coactivator 1, respectively, together with the -galactosidase expression cassette as the reporter. The relative potency, effectiveness and relative inductive efficiency were evaluated by determining the -galactosidase activity (EC 50 ) of each tuberous extract in relation to that induced by 17-estradiol. Six pure compounds isolated from B. superba were tested in parallel and exhibited a maximum relative potency compared to 17-estradiol of 15.5% and 5.27% in the respective hER and hER assays. Eighteen and seventeen plant extracts were respectively found to interact with the hER and hER receptors in the YES assays with higher relative potency and relative inductive efficiency with hER than with hER. The selected plant extracts tested exhibited antiestrogenic activity. Coincubation with the rat liver S9 mixture also elevated the estrogenic potency of these plant extracts.
Erythrina variegata L., a traditional herb in Southeast Asia, India and China has been shown to have estrogenic activity by expressing an anti-oesteoporotic effect in ovariectomized rats.
3) Kudzu, the common tuberous vine of China, Korea and Japan contains a high amount of isoflavonoids [4] [5] [6] whilst ''white kwao krua,'' the common tuberous vine of Thailand, Myanmar and Laos is traditionally consumed for rejuvenating and for treating menopausal symptoms. 7) The tuberous plant materials from P. mirifica have exhibited stronger estrogenic activity than that of Kudzu in ovariectomized rats that was evaluated by both the vaginal cornification assay 8) and uterotrophic assays. 9) Butea superba Roxb., family Leguminosae, with the domestic Thai name of ''red kwao krua,'' is commonly found in deciduous Thai forests and is an indigenous Thai herb popularly used for promoting male potency 7) as well as constituting a minor component of traditional medicines made with P. mirifica for treating menopausal symptoms. It has exhibited androgen disruption in male rats.
10) The efficacy of B. superba powder has been demonstrated in a human clinical trial resulting in the effective treatment of erectile dysfunction in Thai males. 11) B. superba products have recently been becoming popular as traditional medicines, dietary supplements and for topical applications to promote male vigor. The traditional used of this plant ingredient needed to be scientifically evaluated to aid in an understanding of the bioactivity of the plant recipes. We therefore set up a YES-based study to evaluate the estrogenic activity of B. superba tuberous samples collected from available sources in Thailand. The results could make it possible not only to discover why the plant is used in the recipes for treating menopausal symptoms but also to establish the first evaluated record of estrogenic activity in this plant species.
Materials and Methods
Plant materials. The tuberous roots of B. superba were collected from 23 out of the 76 provinces of Thailand during the summer (March-April) of 2000. The plant samples were identified by Cherdshewasart with reference to the herbarium voucher no. BCU 11046.
12) The tuberous roots were cleaned, sliced, dried in a hot-air oven at 70 C, subsequently ground into powder and filtered through a 100-mesh-size sieve. The sieved powder was extracted with absolute ethanol at a ratio of 1:10 (w/v) for 3 d at room temperature, and then the sediment was discarded. The ethanolic supernatant was passed through Whatman no. 3 filter paper, and the filtrate was evaporated in a rotary evaporator to leave a solid ethanolic tuberous extract. Each crude plant extract was kept in a tightly-capped tube, in a lightprotected container and stored at À70 C until needed. A stock solution of each extract was freshly prepared in DMSO at concentrations ranging from 1 Â 10 À3 to 1 Â 10 3 mg/ml.
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Estrogenic activity testing of the six chemicals isolated from B. superba tubers. Five previously isolated chemicals 13) plus hexacosanoic acid 2,3-dihydroxy-propyl ester (Fig. 1) , which had all been isolated from tubers of B. superba collected from Lampang Province, Thailand, were used as reference chemicals in the evaluating the estrogenic activity of the plant extracts. These were presented by Dr. N. Ngamrojanavanich.
Construction of yeast estrogen screening strains ER + hTIF2 and ER + hSRC1. The YES assay was based on a yeast two-hybrid system and constructed by inserting the human estrogen receptor (hER) and coactivator into the yeast cells which allowed specific binding of suitable ligands with ER prior to their interaction with the yeast transcription machinery. The estrogenic activity was quantitatively evaluated by the level of expression of the reporter gene encoding the -galactosidase enzyme. 14) Since hER exists in the two subtypes of hER and hER that are distributed within specific tissues, only human transcriptional intermediary factor 2 (hTIF2) and human steroid receptor coactivator 1 (hSRC1) which have exhibited the greatest respective effectiveness to hER and hER in the presence of 17-estradiol 14) were chosen for evaluating the estrogenic activity of the B. superba tuberous ethanolic extracts and their six isolated chemicals.
Yeast Saccharomyces cerevisiae strain Y190 (MATa, ura3-52, his3-D200, ade2-101, trp1-901, leu2-3,112, gal4Dgal80D, URA3::GALLacZ, cyhr2, LYS2::GAL-HIS3; Clontech Ò , USA) was used as the host for constructing the two yeast strains, YES-hER + hTIF2 and YES-hER + hSRC1, respectively harboring the plasmid pGBT9-hERLBD and pGAD424-hTIF2 coactivator, and plasmid pGBT9-hERLBD and pGAD424-hSRC1 coactivator. Plasmids pGBT9-hERLBD, pGBT9-hERLBD and pGAD424-hSRC1 were constructed by using genes hER/ LBD and hSRC1 kindly provided by Dr. A. Ohta of the Department of Biotechnology, the University of Tokyo, Japan.
15) Plasmid pGAD424-hTIF2 was presented by Dr. Y. Masamune of the Department of Cellular and Molecular Biology, Faculty of Pharmaceutical Science, Kanazawa University. 16) Yeast culture conditions. S. cerevisiae host strain Y190 was maintained on yeast peptone dextrose agar (YPD: 1% (w/v) yeast extract, 2% (w/v) peptone, 2% (w/v) glucose and 2% (w/v) agar). The yeast cells were incubated at 30 C for two days and then preserved at 4 C for routine use. Recombinant S. cerevisiae yeasts were usually selected and grown on a synthetic complete medium (SC) lacking tryptophan and leucine (SC agar: 0.67% (w/v) yeast nitrogen base w/o amino acid, 2% (w/v) glucose, 2% (w/v) dropout mix (lacking tryptophan and leucine) and 1.5% (w/v) agar). Long term preservation was achieved by growing them in SC broth lacking tryptophan and leucine at 30 C to the mid to late logarithmic phase of growth (24 h), when an equal volume of 30% (v/v) glycerol was added and mixed and the yeast samples preserved in 1-ml aliquots at À80
C. In the case of the -galactosidase assay, the recombinant S. cerevisiae yeast samples were grown in a synthetic dextrose minimal medium (SD) broth supplemented with 0.02 mg/ml of adenine at 30 C while vigorously shaking overnight for 14-16 h.
Recombinant yeast assay. The assays were performed by incubating 50 ml of an overnight yeast culture and 2.5 ml of one of (i) an ethanolic tuberous extract (10 À3 -10 3 mg/ml final concentration), or (ii) an individual isolated chemicals from B. superba at 10 À6 -1 mg/ml final concentration, or (iii) 17-estradiol, E2 (10 À2 -10 À10 M final concentration, as a positive control) or (iv) DMSO (the vehicle) in each tube containing 200 ml of a fresh selective medium. After incubating at 30 C while shaking for 4 h, a 150 ml aliquot of each cultured cell suspension was allocated to each well of a 96-well microtiter plate for measurement of the optical density (OD) at 660 nm, and 100 ml was used to harvest the cells by centrifugation at 12;000 g max for 5 min. The resulting cell pellet was then resuspended in 200 ml of a Z-buffer (0.1 M sodium phosphate at pH 7.0, 10 mM KCl, 1 mM MgSO 4 and 3.5 mM -mercaptoethanol) containing 1 mg/ml of zymolyase 20T, and the mixture incubated at 37 C for 15 min. The resulting cell lysate was incubated with 40 ml of a substrate (4 mg/ml of o-nitrophenyl--D-galactoside (ONPG) in a 0.1 M sodium phosphate buffer at pH 7.0) at 30 C for 30 min, the reaction being terminated when the yellow color of o-nitrophenol (ONP) had developed by adding of 100 ml of 1 M Na 2 CO 3 . To remove all the cell debris, the reaction tube was clarified by centrifugation at 12;000 g max for 5 min, then 150 ml of the clarified supernatant was transferred into each well of a 96-well microplate and the absorbance levels at 420 nm and 550 nm were measured by a microplate reader.
14) The experiment was done in triplicate for each sample.
-Galactosidase assay. The -galactosidase activity is defined in terms of Miller units and calculated by the following equation:
Miller unit ¼ 1000½OD 420 À 1:75ðOD 550 Þ=½OD 660 ðtÞðvÞ where OD 420 is the absorbance of yellow ONP, OD 550 is light scattering from the cell debris at the end of reaction, OD 660 is the cell density at the start of the assay, t is the time of reaction (min) and v is the volume of culture used in the assay (ml).
Calculation of the estrogenic EC 50 values for each extract. The yeast cells were incubated with none (control) and with 10 À3 to 10 3 mg/ml of the B. superba tuberous ethanolic extract before the -galactosidase activity was subsequently analyzed. The relative potency, efficiency and relative inductive efficiency were evaluated and then compared with the values obtained from yeast cells incubated with 17-estradiol at a dose of 10 À2 to 10 À10 M as a standardized reference for the estrogenic activity amongst the B. superba plant extracts.
The data obtained from the -galactosidase assays were each fitted with a four-parameter logistic dose-response model. Calculations were performed with Sigmaplot software for Windows, version 9.0 (Microsoft Inc., USA), using the following function;
where Y is the response value (-galactosidase activity), X is the sample concentration in the test, A is the maximum response of -galactosidase activity (ligand efficiency), B is the relative slope of the middle region of the curve as estimated from a linear/log regression of the linear part of the dose-response curve, C is the sample concentration that resulted in 50% efficiency, and D is the detection limit. The EC 50 value is the value of C in the equation and represents the ligand potency.
Preparation and use of the S9 mixture. The in vitro metabolic activation of each sample resulting from the addition of a freshly prepared rat liver S9 mixture, was tested against the tuberous ethanolic extracts from two plant samples that exhibited no detectable estrogenic activity in either of the two YES assays. Thus the plant samples were selected on the basis of their likely sensitivity and ease of detection, since they had a low endogenous estrogenic activity level which would otherwise potentially saturate the assay, masking the newly formed activity by the in vitro hepatic metabolic activation.
A 10-ml aliquot of a plant extract dissolved in DMSO was incubated with a 990-ml aliquot of freshly prepared S9 mixture as described 17) (containing 0.5 mg of the rat liver S9 fraction (Wako Pure Chemical Industries, Ltd., Japan), 0.16 M MgCl 2 , 0.1 M NADP, 0.1 M G-6-P, 0.5 M sodium phosphate buffer at pH 7.4, and 1 M KCl) at 37 C for 4 h. The negative control consisted of the S9 fraction heat-inactivated at 95 C for 5 min. Each S9-treated plant extract was stored at À80 C until needed. The final respective concentrations of S9-treated B. superba and puerarin in the assay were 1000 and 42 mg/ml.
Evaluation of the antiestrogenic activity. The antiestrogenic activity of B. superba was evaluated by examining the tuberous ethanolic extracts that showed no detectable estrogenic activity were examined for anti-estrogenic activity based on their ability to inhibit thegalactosidase induction by 17-estradiol in the YES-hER + hTIF2 and YES-hER + hSRC1 assay systems. These two samples were accordingly selected based on their likely sensitivity and ease of detection of anti-estrogenic activity, since they would either have had too low an estrogenic activity level, relative to any anti-estrogenic activity, to mask overcoming the exogenous 17-estradiol activity.
Statistical analyses. The -galactosidase unit activity presented in this study is presented as the mean AE standard deviation (SD) of three independent experiments. An unpaired Student's t-test and Duncan's multiple-range test were used for analyzing of the test results with p < 0:05 being considered significant, by using SPSS Version 11 statistical software program.
Results

ER-and ER-estrogenic activities
The ER-and ER-estrogenic activities, as respectively determined with the YES-hER + hTIF2 and YES-hER + hSRC1 based assays of the six pure compounds isolated from B. superba are summarized in Table 1 . The relative ER-estrogenic potency of these six isolated B. superba chemicals formed three broad groupings with, in order of potency, group 1 (7-hydroxy-
0 -dimethoxyisoflavone). However, although the ER-estrogenic activity showed the same three groupings, with group 1 also showing the highest potency, that of groups 2 and 3 was reversed such that the actual order in terms of relative potency was; 7-hydroxy-6,4 0 -dimethoxyisoflavone > 7,4 0 -dimethoxyisoflavone > hexacosanoic acid 2,3-dihydroxypropyl ester > medicarpin > formononetin > prunetin.
To evaluate the ER-and ER-estrogenic activities of the B. superba tuberous ethanolic extracts, the relative potency, efficiency and relative inductive efficiency of the plant extracts derived from the YES-hER + hTIF2 and YES-hER + hSRC1 YES assays were compared (Tables 2 and 3 ). The results for the 23 geographical samples of B. superba are ranked in order of the highest relative potency observed for ER (Table 2 ) and ER ( Table 3 ). The mean value for the relative potency of each plant extract by the YES-hER + hSRC1 assay was found to be approximately six-fold greater than that by the YES-hER + hTIF2 assay, this difference being statistically significant (p < 0:05). Presentation in terms of the efficiency and relative inductive potency showed a similar pattern for both. Of some note is the significant variation in both ER and ER activities between the different samples. Whether this was attributable to different geographical locations (cultivars and or cultivation conditions) or occurred with any given cultivation remains to be ascertained.
Anti-estrogenic activity
The plant extracts that expressed very little or no detectable estrogenic activity in the YES-hER + hTIF2 assay (collected from Chaiyaphum Province) and YES-hER assay (collected from Saraburi Province) were selected to screen for the potential anti-estrogenic activity. These two plant extracts clearly demonstrated an anti-estrogenic effect in both these assays, showing clear inhibition of the 17-estradiol effect. The apparent anti-estrogenic activity of both plant extracts was slightly higher in the ER (YES-hER + hSRC1) assay than in the ER assay (YES-hER + hTIF2) assays (Fig. 2) . Regardless of this, these results are consistent with the notion that at least these two, if not all the unmetabolized B. superba tuberous ethanolic extracts harbored anti-estrogenic activity.
In vitro metabolic activation One of the plant samples that exerted very little detectable estrogenic activity in the YES-hER + hTIF2 assay (collected from Chaiyaphum Province) and the one plant showing negative in the YES-hER + hSRC1 assay (collected from Saraburi Province), were tested for potential in vitro hepatic metabolism by coincubating with a fresh S9 mixture prior to assaying for the estrogenic activity. Both the ER and ER estrogenic activities of these two tuberous ethanolic plant extracts were significantly, but differently increased by the S9 mixture treatment, with an enhanced ER-but not ER-estrogenic activity for the sample from the Chaiyapum Province and, conversely, enhanced ERbut not ER-estrogenic activity for the sample from the Saraburi Province (Fig. 3) . These results are consistent with the notion that hepatic metabolism, in this case attained in vitro by incubating with the S9 mixture, could elevate the net estrogenic activity (i.e., that observed above any level of inhibitory anti-estrogenic activity also present) of the B. superba tuberous ethanolic extracts and furthermore, that such enhanced ERor ER-estrogenic activity may be different in different plant extracts, suggesting differing chemical constituents. However, the bioactive compounds so metabolized and the new bioactive compounds so formed remain to be elucidated.
Discussion
We tested in this study, a modified yeast two-hybrid system based upon the human estrogen receptors (ER and ER, separately) coupled to the -galactosidase reporter gene to separately monitor the ER-and ERestrogenic activities in the B. superba tuberous ethanolic extracts as well as those in six pure chemicals that had previously been isolated from B. superba tubers.
The YES-hER + hTIF2 based assay revealed highly potent ER-estrogenic activity with 7-hydroxy-6-4 0 -dimethoxyisoflavone at a level broadly comparable to that of the 17-estradiol positive control. Moderately good ER-estrogenic activity, and thus assumed binding and or activation, was also apparent with medicarpin and formononetin. However, the other three compounds each showed a much weaker ER-estrogenic activity, the weakest ER-estrogenic activity being observed with 7,4 0 -dimethoxyisoflavone. This highlights the diverse variation in estrogenic activity amongst the compounds.
With respect to the ER-estrogenic activity, 7-hydroxy-6-4 0 -dimethoxyisoflavone also exhibited by far the strongest activity of the six compounds, and thus could bind strongly and activate both ER and ER. However, its ER-estrogenic activity was less than that of the 17-estradiol positive control. Moreover, medicarpin and formononetin, which had moderate ER-estrogenic activity, showed only a weak level of ER-estrogenic activity, whilst 7,4 0 -dimethoxyisoflavone and hexacosanoic acid 2,3-dihydroxy-propyl ester, which both showed weak ER-estrogenic activity, revealed a moderate ER-estrogenic activity. This means that the B. superba tuberous ethanolic extracts would have been likely to initiate binding to both the human ER and ER receptors with different affinity depending upon their relative chemical constituents.
Importantly, variation between the B. superba samples in their estrogenic activity was apparent in this study. The majority of the plant extracts expressed a detectable, but low level of both ER-and ERestrogenic activity. However, the plant estrogenic activity was classified as of low efficiency in all 23 samples, this was especially true for the ER-estrogenic activity which was some four-to six-fold lower than the corresponding ER-estrogenic activity, depending on which parameter was used for calculating the estrogenic activity. The clear suggestion is that the non-metabolized phytochemicals in the B. superba tuberous ethanolic extracts could bind to and activate ER more strongly than ER, at least with these two different YES constructions. However, it should be noted with these YES assays that 17-estradiol bound or activated ER more strongly than ER with the same YES constructions. This correlates with a previous finding in a study on soy isoflavonoids that those phytoestrogens could bind to or activate ER more strongly than ER whilst estrogen bound to ER more strongly than to ER.
16)
The results of this present study also showed variation in the estrogenic activity of the plant samples collected from different provinces in Thailand although there was not a sufficient number of samples from within each of the 23 localities to distinguish intra-regional variation from inter-regional variation. Nevertheless, the results were not directly related to the region of the existent plant samples. This implies the likely combined influence of the environment, plant age/development stage and plant genetics on such bioactive difference. There was no assay on the concentration of the six isolated compounds in all analyzed samples, except for the one collected from Lampang Province. It is correspondingly not possible to correlate the estrogenic activity of the plant samples with the six chemicals isolated in this study. The tuberous ethanolic extracts from B. superba that did not exhibit estrogenic activity in the YES-hER + hTIF2 and YES-hER + hSRC1 based assays, did exhibit anti-estrogenic activity in the incubation assay with 17-estrodiol. However, this result was obtained with non-metabolized samples whereas the oral administration of herbs like B. superba would be likely to result in hepatic metabolism. Such hepatic metabolism may enhance or reduce any anti-estrogenic activity, an aspect which was not assayed here. The potential importance of this point is illustrated by the estrogenic activity, whereby the addition of an in vitro hepatic metabolizing S9 system clearly increased the net observed estrogenic activity of the two B. superba samples tested and differentially increased the ERbut not ER-estrogenic activity in one plant extract, but visa versa in the other sample.
Various methods have been used to evaluate the estrogenic activity of phytoestrogens or plant materials. The uterotrophic assay with ovariectomized rats is a classical method and has been used to establish the estrogenic activity in phytoestrogen-rich plants. 18) The vaginal cornification assay is a simpler method that is performed with ovariectomized rats, and has also enabled the successive differential evaluation of estrogenic activity for the phytoestrogen-rich Pueraria mirifica and P. lobata populations. 8, 19) The MCF-7 screening test (E-assay), based on the estrogen-dependent in vitro proliferation of the human mammary adenocarcinoma cell line in the presence of a tested phytoestrogen, has been able to demonstrate the biphasic estrogenic response of the phytoestrogen-rich B. superba and P. mirifica extracts 12, 20) and has also revealed that this was dependent on where the plant samples were collected. Our previous analysis using an MCF-7 proliferation assay of the same plant samples of B. superba collected from Lampang Province as those used in this study, found no proliferative effect but instead an antiproliferative effect in the tested dose Fig. 3 . Estrogenic Activity of the B. superba Tuberous Ethanolic Extracts after Treating with the Rat Liver S9 Fraction Evaluated by the YEShER + hTIF2 and YES-hER + hSRC1 Assays. Abbreviation: S9-inactive is the heat-inactivated S9 fraction (negative control): S9-active is the active S9 fraction. Each value is the mean of three independent experiments. The final concentration of each S9-treated B. superba tuberous ethanolic extracts at 1000 mg/ml and of puerarin (control) at 42 mg/ml was tested. Data are expressed as the mean AE SD, n ¼ 3.
Ã p < 0:05; significantly different from the S9-inactive treatment by Student's t-test. A plant sample at a 10 3 mg/ml, final concentration of was mixed with 17-estradiol at a 10 À9 M final concentration and determined against the same concentration of 17-estradiol (as a control). Data are expressed as the mean AE SD, n ¼ 3.
Ã p < 0:05; significantly different from the 17-estradiol treatment by the Student's t-test.
range of 10-1000 mg/ml. 12) In contrast to the results with the MCF-7 assay, most of the B. superba samples in this YES-based study, including those from Lampang Province, exhibited estrogenic activity in the yeast twohybrid system suggesting this hybrid system to be more sensitive than the standard MCF-7 cell proliferation test in determining the potential net estrogenic activity, especially of plant materials. However, these two test systems involve no hepatic metabolic activation and are theoretically unlikely to represent the real situation following an oral administration, indeed, the estrogenic activity of P. mirifica experimentally assayed with HepG2 cells has suggested the requirement for hepatic activation to demonstrate maximal estrogenic activity. 21) In contrast, the establishment of the YES test system in the presence of an S9 mixture comprising rat liver enzymes that was used in this study supports our previous finding that in vitro metabolic activation could enhance the estrogenic activity of the plant extracts. 22) Even though the in vitro YES assay is a rapid method and could be quantitatively applied, it may not have the high level of sensitivity for detecting estrogenic activity that the in vivo vaginal cornification assay offers. Moreover, it may not be possible to reliably apply the results from the same plant materials in tests with animals to predict what would be the case with human consumption. Moreover, the successful detection of estrogenic activity in tuberous ethanolic extracts from diverse B. superba samples provides additional support for the efficacy of the in vitro yeast two-hybrid system for detecting estrogenic, and perhaps anti-estrogenic, activity. This system has previously been used to study estrogens in such other plants as Moghania philippinensi, 23) the traditional Chinese herb, Polygonum cuspidatum, 24) several Mediterranean plants 25) and Millettia pachycarpa. 26) We demonstrated in this study that most of the Thai B. superba populations showed detectable estrogenic activity and also potentially anti-estrogenic activity. The anti-estrogenic activity of the B. superba tuber extract is in accordance with the study of B. superba samples collected from Lampang Province by a hormonal assay and histological assay of the uterus in ovariectomized rats. 27) This might be one of the reasons why the plant is used in the recipes for treating menopausal symptoms. The YES test systems could provide useful information in screening potential B. superba material for further developing phytoestrogenrich products, especially in conjugation with the S9 in vitro hepatic metabolic activation.
